SecBot SecBot

ALNY drug pipeline

$159.73
−3.2% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±1.7%
1-day, median of 5 events
IV rank
No data
No current options data
Rated drugs
7
7 neutral
Phase 3 trials
1
1 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 1b
Time to marketIf the pivotal study begins in 2027 as planned, a potential approval would be several years away, likely 2029-2031 assuming positive Phase 3 data and a standard FDA review timeline.

brezosiran Updated Oct 29

What to watch

The next catalyst for brezosiran is the planned initiation of a placebo-controlled pivotal study in 2027, pending regulatory alignment. Positive Phase 1b data (60-64% mean mHTT reduction) supports advancement, but the drug is still early-stage and represents a small part of Alnylam's diversified, approved-product portfolio. Watch for regulatory feedback and trial design details in 2027.

Bull case
  • Phase 1b data showed best-in-class huntingtin knockdown: mean 60-64% reduction of CSF mutant huntingtin at month 3 in the highest dose group, with individual reductions up to 83%, surpassing competitors like WVE-003 (46%).
  • Encouraging safety and tolerability profile with potential for convenient twice-yearly dosing via intrathecal administration, which could enhance patient adherence.
  • Alnylam plans a placebo-controlled pivotal study in 2027, which would be the first placebo-controlled test of the huntingtin 1a-lowering hypothesis, a potentially landmark trial.
Bear case
  • Phase 1b data do not establish clinical efficacy; the drug has not yet shown it can slow Huntington's disease progression, only that it lowers a biomarker (mHTT protein).
  • Brezosiran is non-selective, lowering both normal and mutant huntingtin protein, which carries theoretical safety risk since normal huntingtin has important biological functions.
  • The competitive landscape includes Wave Life Sciences' WVE-003 (allele-selective ASO with 46% mHTT reduction and FDA alignment for accelerated approval), and Roche's tominersen failure highlights how difficult it is to translate biomarker knockdown into clinical benefit in Huntington's.
● neutral
Impact
PhaseApproved (FDA approval 2019-11-20)
Time to marketAlready approved and on the market — FDA approval recorded 2019-11-20; no new regulatory decision pending.

GIVLAARI givosiran Updated Aug 1

What to watch

Watch Alnylam's quarterly earnings for the TTR-franchise trajectory and total product revenue, since GIVLAARI's own newsflow is minimal now that it is approved, do not expect a Givlaari-specific binary in the next 12 months. For a trade on ALNY itself, the near-term drivers are the ATTR-CM (vutrisiran/patisiran) commercial ramp and the Regeneron cemdisiran NDA (filed 2026-04-30), not this drug. Re-verify the drug's label/mechanism and any competitive or pricing news with live web sources, since DuckDuckGo was unavailable during this session.

Bull case
  • Regulatory binary is behind it: GIVLAARI already won FDA approval with a +13.55% 1-day / +14.8% 5-day stock reaction, no approval risk remains for this drug.
  • It addresses a genuine unmet need as a first-in-class RNAi treatment for acute hepatic porphyria attacks, giving it a defensible niche in an ultra-rare indication.
  • Parent company sentiment is broadly constructive: analyst consensus shows 21 Buy + 8 Strong Buy vs 9 Hold and 0 Sell, with a mean price target of $427.61 vs a ~$205.52 quote (implied upside ~106.8%), and Q2 2026 revenue grew ~74% YoY per the local 8-K earnings analysis.
Bear case
  • AHP is ultra-rare, so GIVLAARI's commercial ceiling is small, it is a minor product within a company whose stock is primarily driven by the TTR franchise (vutrisiran/patisiran), meaning Givlaari-specific news rarely moves ALNY.
  • ALNY shares have been hammered: -39.5% over 12 months, -40.7% over 6 months, RSI ~23.5, and a -59 composite quant score as of 2026-07-31, the dominant narrative is the TTR launch slowdown, not this drug.
  • Q2 2026 results missed: non-GAAP EPS $1.84 vs $2.15 consensus and revenue $1.291B vs $1.32B, with FY2026 TTR net product revenue guidance cut from $4.4-4.7B to $4.2-4.5B, the local earnings analysis rated the release bearish (impact 7).
● neutral
Impact
PhaseApproved (marketed); Phase 3 (APOLLO-B) completed
Time to marketAlready approved and marketed — FDA approval recorded 2018-08-10; no new indication approval pending in local FDA records.

ONPATTRO patisiran Updated Aug 1

What to watch

Do not position in ALNY for an ONPATTRO-specific catalyst, there isn't one on the horizon; treat ONPATTRO as a slowly amortizing cash-flow asset whose quarterly revenue lines (Q2 2026 10-Q filed 2026-07-30) are worth watching inside ALNY's earnings for the pace of patient transition to newer franchise drugs. ALNY's mean analyst target of ~$427.61 (observed 2026-07-31) implies the market values the pipeline, not this legacy product, so any trade thesis should hinge on the rest of the portfolio (e.g., cemdisiran) rather than ONPATTRO.

Bull case
  • Approved and on the market: local FDA catalyst records show an FDA approval for ONPATTRO on 2018-08-10, giving Alnylam a durable commercial product and making it one of the earliest RNAi medicines to reach patients.
  • Phase 3 cardiomyopathy program completed: APOLLO-B (NCT03997383, 360 patients) is marked COMPLETED with results, preserving optionality around the ATTR-cardiomyopathy patient population that has become a major franchise battleground.
  • Parent-company support: ALNY carries 29 Buy/Strong-Buy ratings vs 9 Hold and 0 Sell (2026-07-01 consensus), with a mean analyst price target of $427.61 vs a ~$205.52 price (observed 2026-07-31), though this reflects the whole pipeline, not ONPATTRO alone.
Bear case
  • No upcoming binary: ONPATTRO has no pending PDUFA/pivotal readout in the next ~12 months, the approval binary passed in 2018, so the drug itself offers little catalyst-driven upside; per the impact rubric an approved drug with no pending decision caps at 5 and this legacy product scores 3.
  • Legacy-product risk: ONPATTRO is an older IV-infusion RNAi in a franchise Alnylam has since moved beyond (its recent FDA catalyst filings concern other drugs), raising internal-cannibalization and revenue-decline risk that this session's local data cannot quantify.
  • Cardiomyopathy path is not confirmed: APOLLO-B completed, but no FDA action or new approval for ONPATTRO in cardiomyopathy appears in local FDA/catalyst records, a label-expansion win cannot be assumed.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercialized — FDA approval catalyst recorded 2020-11-23; it has been on the market for years.

OXLUMO lumasiran Updated Aug 1

What to watch

OXLUMO itself is not a near-term stock driver, do not trade ALNY on it. Watch Alnylam's quarterly earnings for OXLUMO's contribution and the pipeline catalysts that actually move the stock: the cemdisiran NDA (submitted to FDA 2026-04-30 for generalized myasthenia gravis) and zilebesiran/nucresiran readouts; ALNY is currently deeply oversold (RSI ~23.5) after a Q2 2026 EPS/revenue miss and full-year TTR guidance cut.

Bull case
  • Approved and on the market: SecBot catalyst records show an FDA approval for OXLUMO (ALNY) on 2020-11-23, and the Q2 2026 earnings filing analysis lists OXLUMO among Alnylam's four commercial products, it generates revenue with no remaining regulatory binary risk.
  • Wall Street is broadly positive on the owner: ALNY analyst consensus is 29 Buy/Strong-Buy vs 9 Hold and 0 Sell, with a mean price target of $427.61 versus the $205.52 price, roughly 106.8% implied upside per ticker_overview (2026-07-31).
  • The stock's reaction to the OXLUMO approval catalyst itself was positive but calm (+0.77% 1-day, +4.14% 5-day), typical of a niche product approval, no binary overhang left.
Bear case
  • No hard, dated catalyst for OXLUMO in the next ~12 months: it has been approved since Nov 2020, and the drugs that actually move ALNY now are the TTR franchise and pipeline (cemdisiran NDA 2026-04-30; zilebesiran, nucresiran, mivelsiran), OXLUMO is a minor part of the story.
  • Company-level tape is bearish: ALNY reported Q2 2026 non-GAAP EPS $1.84 vs $2.15 consensus (-14.4%) and revenue $1.291B vs $1.32B (-2.2%), and cut full-year TTR net product revenue guidance from $4.4B-$4.7B to $4.2B-$4.5B (local analysis of the 2026-07-30 8-K).
  • Technical/quant picture is weak: ALNY at $205.52 sits ~41% below its 200-day SMA ($349.29), RSI 23.5 (oversold), MACD bearish cross, and quant composite -59 (7/31/2026 snapshot); short interest ~4.32% of estimated shares outstanding with ~3.24 days-to-cover as of the 7/15/2026 settlement.
● neutral
Impact
Phaseunknown (no registered ClinicalTrials.gov record found; appears to be an early, minimally disclosed pipeline program)
Time to marketunknown — no clinical trial or development phase disclosed in any retrievable source

ALN-6222 Updated Aug 1

What to watch

ALN-6222 is real (it appears in Alnylam's Q2 2026 pipeline listing in the 8-K filed 2026-07-30) but is essentially undisclosed, no target, indication, or clinical trial could be found. Investors should not trade ALNY on this code; wait for Alnylam corporate/R&D pipeline updates (typically year-end R&D events) to disclose the program's target and phase, and treat any news as early-stage speculation. Company-level drivers (TTR franchise guidance, zilebesiran/mivelsiran readouts) are what actually move ALNY.

Bull case
  • ALN-6222 is an officially listed program in Alnylam's pipeline disclosure (Q2 2026 earnings 8-K, filed 2026-07-30), confirming it is an active corporate program rather than a defunct code.
  • It sits on Alnylam's proven RNAi platform inside a financially strong company: Q2 2026 total revenue was $1.291B (+67% YoY) with $3.3B cash and marketable securities (per the 8-K analysis), so early pipeline programs are well funded.
  • The stock-level setup is contrarian: analyst consensus remains bullish (21 Buy + 8 Strong Buy, 0 Sell; mean price target $427.61 vs. ~$204 price, ~107% implied upside per the 2026-07-31 consensus snapshot), though this is company-wide and not drug-specific.
Bear case
  • No public information exists on ALN-6222's target, indication, or phase, it has no ClinicalTrials.gov registration, FDA record, press release, or analyst coverage in any tool result; early-stage RNAi programs carry high preclinical attrition risk.
  • There is no dated catalyst for this drug within ~12 months (no PDUFA, no pivotal readout, no IND/trial registration found), so it cannot drive a scheduled binary event for ALNY.
  • Company-level headwinds dominate: Q2 2026 non-GAAP EPS of $1.84 missed consensus of $2.15 and FY 2026 TTR revenue guidance was cut to $4.2B-$4.5B (bearish earnings analysis, impact 7); the stock is down ~31.9% in 1 month and ~39.5% over 12 months (quant snapshot 2026-07-31), with FINRA short interest ~4.32% of estimated shares outstanding and persistently elevated daily short-volume ratios (~48-69%).
● neutral
Impact
PhaseNot stated
Time to marketunknown — no clinical or regulatory stage could be verified

ALN-2232 Updated Aug 1

What to watch

Do not trade ALNY on the basis of ALN-2232, there is no verifiable evidence this candidate is a disclosed clinical-stage program, and it cannot be distinguished from an early/undisclosed preclinical code or a data-entry artifact. Watch Alnylam's official pipeline disclosures (10-K/10-Q, investor day) for any first mention of ALN-2232 before assigning it any value; company-level catalysts that ARE documented (e.g., Regeneron's cemdisiran NDA submission for generalized myasthenia gravis on 2026-04-30) are unrelated to this code.

Bull case
  • If ALN-2232 is a real but undisclosed early-stage Alnylam candidate, it inherits the platform and balance sheet of a proven RNAi developer: the company's Q2 2026 filings show strong product revenue growth and analyst consensus is Buy-leaning (21 Buy + 8 Strong Buy vs 9 Hold, per local analyst snapshot).
  • Institutional accumulation was detected in Q2 2026 (four tracked managers net-buying ~$15M, zero sellers, per local institutional-cluster report), indicating continued professional interest in the ALNY story overall.
Bear case
  • Zero verifiable evidence of clinical or regulatory progress: no trial, no FDA record, no catalyst, and no press coverage of ALN-2232 was retrievable this session, it may be preclinical, inactive, or a non-existent code.
  • Company-level headwinds documented this session: Q2 2026 EPS of $1.84 missed consensus of $2.15, revenue of $1.291B missed $1.32B, and FY2026 TTR net revenue guidance was cut to $4.2B-$4.5B (per local earnings report and 8-K).
  • ALNY stock is under severe technical/quant pressure regardless of pipeline news: 1-month return -31.9%, RSI-14 of 23.5, and composite quant score of -59 (local snapshot as of 2026-07-31).
● neutral
Impact
Phaseunknown (no public trial record found)
Time to marketunknown — no clinical trial or development stage could be verified

ALN-5288 Updated Aug 1

What to watch

Treat any claim about this specific drug as unverified, the stock's near-term drivers are other programs (e.g., the April 2026 cemdisiran NDA submitted by Regeneron), not ALN-5288.

Bull case
  • Parent company is a legitimately large-cap, well-covered RNAi developer: 29 of 38 rated analysts are Buy/Strong Buy with a mean price target of ~$427.61 vs. ~$204.20 current, and Alnylam files regularly with the SEC (10-Q filed 2026-07-30).
  • If ALN-5288 is a genuine early-stage Alnylam candidate, it would sit inside a pipeline with proven RNAi delivery and multiple marketed drugs, but this is inference about the platform, not evidence about this drug.
  • Recent tracked-manager 13F data shows institutional accumulation in ALNY (multiple new/add/doubled positions in 2026-Q1/Q2 filings), indicating broad sponsorship of the company, not of this molecule.
Bear case
  • With no mechanism, indication, or trial stage verified, any investment thesis built on this code is speculation; there is no dated catalyst to trade, so the stock cannot be expected to move on ALN-5288 in the next 12 months.
  • Company-level context is not all bullish: the 90-day evidence checklist also logged insider Form 4 sales (director David Pyott, June 2026, 10b5-1-plan flagged), several tracked-manager exits/severe trims, and a weighted short-volume ratio of ~0.48 over 60 sessions, noise for this drug, but it underscores that ALNY's price action is driven by its other programs.

Other drugs in filings and trials

no drug report yet
  • cemdisiran Last: NDA filed · Apr 30, 2026
  • AMVUTTRA Last: Approval · Jun 13, 2022
  • Zilebesiran 2 trials

Past FDA events & how the stock moved

5 events
DateDrugEvent1 day5 days
Apr 30, 2026cemdisiranNDA filed−1.7%−1.8%
Jun 13, 2022AMVUTTRAApproval+1.1%+5.2%
Nov 23, 2020OXLUMOApproval+0.8%+6.1%
Nov 20, 2019GIVLAARIApproval+13.6%+20.0%
Aug 10, 2018ONPATTROApproval−3.5%+0.3%

Clinical trials

3 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
ZilebesiranA Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate HypertensionPhase 2Completed · results36Jul 17, 2025
ZilebesiranZilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)Phase 2Completed375Jun 19, 2025
ONPATTROAPOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)Phase 3Completed · results360Jun 20, 2022